Navigation Links
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Date:10/7/2008

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week

PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical Psychiatry found once-daily VYVANSE significantly improved Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults within the first week of treatment. This study is the phase 3 pivotal trial submitted to the FDA and supported the approval in April 2008 of VYVANSE for adults with ADHD. VYVANSE was introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years and is now the fastest-growing ADHD prescription medication in the United States.

"This study adds to the growing body of research of ADHD in adults, and showed that VYVANSE provided effective symptom control for adults with this disorder," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "It is important for people to realize that in adults, the core symptoms of ADHD -- inattention, hyperactivity, and impulsivity -- may present as inner restlessness, a lack of focus and organization, poor time management, or an inability to finish tasks, which can impact adults' daily lives. In this study, VYVANSE was shown, within the first week, to significantly improve ADHD symptoms of inattention, such as the ability to focus and organize, and hyperactivity and impulsivity, such as restlessness, and interrupting."

VYVANSE Significantly Improved ADHD Symptoms in Adults

In this randomized, double-blind, placebo-controlled, par
'/>"/>

SOURCE Shire Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Inhibikase Therapeutics, Inc. today announced the election ... Directors of Inhibikase Therapeutics, Inc. ... Cubist Pharmaceuticals in 2008 and currently serves as ... and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, ...
... 2011 Codexis, Inc. (Nasdaq: CDXS ) today ... June.   The company will participate in the ... held in New York, NY on June 1-2, 2011. Alan ... a panel titled "Renewable Biomaterials", scheduled for June 1 at ...
Cached Medicine Technology:Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors 2Codexis to Present at 3 Investor Conferences in June 2
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... , , NEW YORK , Jan. ... information management industry leader, and Catalyst Repository Systems, Inc. ... for electronic discovery and regulatory compliance, jointly announced today ... legal document review market by offering ISO 9001:2008-certified Legal ...
... known that people who live or work in rural areas ... compared to those in more urban environments. But while time ... new research suggests that limited access to early, high-quality trauma ... Researchers from St. Michael,s in Toronto looked at 3,486 ...
... CITY University of Utah researchers led an international ... on the previously undescribed ability of platelets to reproduce ... online Jan. 19, 2010, in the journal Blood ... the bone marrow, a process that is called thrombopoiesis. ...
... , ... through Public Standards. , ... Rockville, MD (Vocus) January 26, 2010 -- The United States Pharmacopeial Convention (USP) ... Member delegates and experts from around the world will gather to discuss pressing global ...
... Celebrate ... ... and Oldways and the Mediterranean Foods Alliance offer 10 ways to ... Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean Diet is one ...
... up to $2,750, , TUESDAY, Jan. 26 (HealthDay News) -- ... banned from using a handheld device to send text messages, ... by the trucking and bus industry, goes into effect immediately, ... Secretary Ray LaHood said during a morning press conference. , ...
Cached Medicine News:Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 2Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 3Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 4Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 5Health News:BIA and Catalyst Release Per-Document Review & Hosting, a Cost-Effective Package 6Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Groundbreaking research shows platelets can reproduce in circulation 2Health News:Public Health in Focus at International Conference 2Health News:Public Health in Focus at International Conference 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3Health News:U.S. Bans Texting by Truck and Bus Drivers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: